Health Insight
In this issue
-
Approval Without Access: Bridging the Gap From Research to Care
Health Canada approval confirms a therapy is safe and effective, however, this does not guarantee public coverage. For Canadians living with Duchenne muscular dystrophy, that gap can have lasting consequences. Canadian investigators, clinical sites, and families helped advance the evidence for the first and only therapy specifically approved for a neuromuscular disorder, Duchenne muscular dystrophy...
-
s Sponsored
Closing the Gap Between Innovation and Access in Duchenne Muscular Dystrophy
Canada’s Duchenne community is advancing research, but regulatory and access gaps continue to delay promising therapies for families. For the approximately 800 to1,000 Canadians living with Duchenne muscular dystrophy, a rare, progressive neuromuscular disease, the gap between scientific progress, regulatory approval and access can have profound consequences. Since 1995, Defeat Duchenne Canada has invested $20.3...
-
s Sponsored
Time Is Muscle: Canada Is a Leader in Duchenne Research. Why Are Treatments Still Out of Reach?
Canadian patients and families have helped advance promising Duchenne therapies through research, yet access to those treatments continues to lag behind other countries. For a disease where every year can mean lost muscle function, Canada needs to close the gap between innovation and access. For the approximately 800-1000 Canadians living with Duchenne muscular dystrophy, scientific...
-
s Sponsored
Why Awareness is a Critical Tool in Better Care for Huntington Disease Patients
This Canadian nonprofit is broadening awareness for a debilitating rare disease impacting Canadians, highlighting an immediate need for more accessible care. It’s the worst disease you’ve never heard of. Huntington Disease (HD) is a rare, fatal genetic neurodegenerative disorder that affects one in every 7,000 Canadians. The debilitating condition appears between the ages of 35...
-
Improving Access to Innovative Care for Canadians Living with Autoimmune Neuromuscular Conditions
Earlier diagnosis, specialized care, investment in research, and access to innovative medicines can improve outcomes for Canadians living with gMG and CIDP. Generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP) are rare autoimmune neuromuscular conditions that can have life-altering impacts. gMG affects the neuromuscular junction, which is the connection between nerves and muscles....
-
Advancing Brain Health Across Canada
Canada is strengthening brain health through coordinated federal action, research investments, national strategies and partnerships aimed at improving outcomes for people living with neurological conditions. Brain health is an important part of the health and well being of Canadians. Our government recognizes the significant impact that brain and neurological diseases, disorders, injuries and other health...
-
s Sponsored
Federal Investment in ALS National Strategy Will Ensure No Canadian is Left Behind
Research into why Canadian military veterans have a higher likelihood of ALS could help advance care and treatment for all Canadians. Bob Gibson is a Canadian military veteran living with amyotrophic lateral sclerosis (ALS). Also known as Lou Gehrig’s disease, ALS is a progressive neuromuscular disease that destroys nerve cells in the brain and spinal cord. As these cells...
-
s Sponsored
Canada Can No Longer Wait for a National Strategy on Brain Injury
Canada’s fragmented approach to brain injury comes at a significant human and economic cost. Every day, Canadians sustain brain injuries that change the course of their lives. Brain injury does not discriminate as it affects people of every age, gender, culture, income level, and community. Yet for many, recovery means navigating a fragmented system with...